Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone206-325-6068
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions
What is Atossa Genetics' stock symbol?
Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."
When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?
Atossa Genetics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.
How were Atossa Genetics' earnings last quarter?
Atossa Genetics Inc (NASDAQ:ATOS) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.01. View Atossa Genetics' Earnings History.
When is Atossa Genetics' next earnings date?
What price target have analysts set for ATOS?
1 analysts have issued 1-year price targets for Atossa Genetics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Atossa Genetics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price. View Analyst Price Targets for Atossa Genetics.
What is the consensus analysts' recommendation for Atossa Genetics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atossa Genetics.
Has Atossa Genetics been receiving favorable news coverage?
Headlines about ATOS stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atossa Genetics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Are investors shorting Atossa Genetics?
Atossa Genetics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totalling 394,990 shares, a decrease of 55.0% from the March 29th total of 877,358 shares. Based on an average daily trading volume, of 527,193 shares, the days-to-cover ratio is presently 0.7 days. Currently, 7.3% of the company's shares are short sold. View Atossa Genetics' Current Options Chain.
Who are some of Atossa Genetics' key competitors?
Some companies that are related to Atossa Genetics include Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), Nuvectra (NVTR), Motus GI (MOTS), CAS Medical Systems (CASM), STRATA Skin Sciences (SSKN), Repro-Med Systems (REPR), RA Medical Systems (RMED), Titan Medical (TMDI), Invo Bioscience (IVOB), Pro-Dex (PDEX), Spectral Medical (EDTXF), AIT Therapeutics (AITB), Arch Therapeutics (ARTH) and Nephros (NEPH).
What other stocks do shareholders of Atossa Genetics own?
Who are Atossa Genetics' key executives?
Atossa Genetics' management team includes the folowing people:
- Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
- Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
- Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
- Dr. Jack Cuzick, Member of Scientific Advisory Board
Who are Atossa Genetics' major shareholders?
Which major investors are selling Atossa Genetics stock?
Which major investors are buying Atossa Genetics stock?
How do I buy shares of Atossa Genetics?
Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atossa Genetics' stock price today?
One share of ATOS stock can currently be purchased for approximately $2.61.
How big of a company is Atossa Genetics?
Atossa Genetics has a market capitalization of $23.82 million. The company earns $-11,400,000.00 in net income (profit) each year or ($5.50) on an earnings per share basis. Atossa Genetics employs 4 workers across the globe.
What is Atossa Genetics' official website?
How can I contact Atossa Genetics?
Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6068 or via email at [email protected]
MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
